Balchem Corp. Q1 2002 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2002. Balchem Corporation develops, manufactures, and markets specialty performance ingredients for food, feed, and medical sterilization industries. The company operates through three segments: Specialty Products, Encapsulated/Nutritional Products, and Unencapsulated Feed Supplements (the latter resulting from a June 2001 acquisition of assets from DCV, Inc. and DuCoa L.P.).
Key Financial Metrics
| Metric | Q1 2002 | Q1 2001 |
|---|---|---|
| Net Sales | $14,389 | $8,024 |
| Gross Profit | $5,294 | $3,542 |
| Gross Margin | 37% | 44% |
| Operating Income | $2,426 | $1,417 |
| Net Earnings | $1,438 | $1,113 |
| Diluted EPS | $0.29 | $0.23 |
| Operating Cash Flow | $2,676 | $2,371 |
| Total Debt (Current + Long-term) | $12,633 | $0 |
| Cash and Equivalents | $4,565 | $4,722 |
Note: All dollar amounts in thousands except per share data.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 79% to $14.4 million, driven primarily by the Encapsulated/Nutritional Products segment (up 124%) and the new Unencapsulated Feed Supplements segment ($2.7 million). Specialty Products sales grew modestly by 3%.
- Margin Compression: Gross margin declined from 44% to 37%. Management attributes this to increased sales of lower-margin feed products in the unencapsulated segment and product mix changes in the encapsulated segment.
- Debt and Interest: The company incurred $105 in interest expense compared to $8 in the prior year due to a $13.5 million term loan taken in June 2001 to fund the DCV acquisition. Total debt stands at approximately $12.6 million.
- Operating Expenses: Increased 35% to $2.9 million, largely due to added personnel in sales, marketing, and R&D to support the expanded business. However, operating expenses as a percentage of sales decreased from 27% to 20%.
- One-Time Items: Q1 2001 included $324 in "Other income" from a class-action antitrust litigation settlement, which was not present in Q1 2002.
Guidance, Outlook, and Risks
- Capital Expenditures: Projected to be approximately $8,000 for calendar year 2002. Funds are being used to expand manufacturing and distribution facilities in Verona, Missouri, and for new office space.
- Contingent Consideration: The company may owe up to an additional $2,750 related to the DCV acquisition based on future sales and gross margin performance. No amount has been earned or paid as of March 31, 2002.
- Accounting Changes: The company adopted SFAS No. 142 effective January 1, 2002, ceasing the amortization of goodwill. A transitional impairment test is ongoing, but management does not expect a material charge.
- Liquidity: The company maintains a $3,000 revolving credit facility (undrawn) expiring May 31, 2002, which it intends to renew. Management expects operations to generate sufficient cash flow for working capital and debt obligations.
- Risks: Exposure to interest rate fluctuations on the variable-rate term loan (LIBOR + 1.25%). A 100 basis point increase would raise annual interest expense by approximately $126.
Investor Verification Checklist
- Verify the sustainability of the 124% growth in the Encapsulated/Nutritional Products segment and whether it is driven by organic growth or the full-year impact of the 2001 acquisition.
- Monitor the gross margin trend, specifically the impact of the lower-margin unencapsulated feed supplements on overall profitability.
- Confirm the renewal status of the $3,000 revolving credit facility expiring May 31, 2002.
- Track the progress of the SFAS No. 142 goodwill impairment test, with results due by June 30, 2002.
- Assess the potential cash outflow for the contingent consideration ($2,750 max) tied to the DCV acquisition performance metrics.